The National Institute of Neurological Disorders and Stroke (NINDS), a civilian federal agency, has awarded Psychogenics Inc., a for-profit preclinical contract research organization, a $69.1 million cost-plus-fixed-fee delivery order contract to provide screening of investigational agents through the NINDS Preclinical Screening Platform for Pain (PSPP) program. This delivery order is part of a larger $49.9 million single-award indefinite delivery contract between NINDS and Psychogenics to support the agency's mission of transforming the understanding and treatment of neurological diseases. The PSPP is being established to evaluate potential non-addictive pain treatments in support of the NIH's Helping to End Addiction Long-term (HEAL) initiative. Under this contract, Psychogenics will be responsible for in-vitro and in-vivo testing of contributor-submitted investigational agents, including evaluating efficacy, pharmacokinetics, side effects, and abuse liability across a range of pain models. The contract has no set-aside designation and is set to run through September 2029.
Generated 9/19/24, 9:05 AM